HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial - Scorecard - MDSpire

HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial

  • By

  • Lixin Guo

  • Zilin Sun

  • Lihui Zhang

  • Guijun Qin

  • Yulan Li

  • Xiaopan Chen

  • Na Xu

  • Xiuhai Su

  • Li Mao

  • Jiao Sun

  • Zhifeng Cheng

  • Xiaoguang Shi

  • Fang Wang

  • Qi Wang

  • Ruirong Pan

  • Shan Ding

  • Zi Ye

  • Yimei Xu

  • Pan Liu

  • June 3, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of HRS-7535 in Patients with Type 2 Diabetes Not Adequately Managed by Metformin: Results from a Randomized Clinical Study

At a Glance

CategoryDetail
Condition
Key MechanismsGLP-1 receptor agonism, reduced appetite
Target Population
Care Setting

Key Highlights

  • The trial included a 16-week double-blind treatment period.
  • Primary endpoint was change in HbA1c level at week 16.
  • Safety profile consistent with other GLP-1 RAs.
  • Participants had an HbA1c level of 7.5% to 11.0% despite metformin therapy.

Guideline-Based Recommendations

Diagnosis

    Management

    • HRS-7535 administered as add-on therapy to metformin, as per trial protocol.

    Monitoring & Follow-up

    • Assess HbA1c levels and monitor for adverse events as per trial protocol.

    Risks

    • Monitor for liver function abnormalities and hypoglycemic events as per trial protocol.

    Patient & Prescribing Data

    HRS-7535 showed a safety profile consistent with other GLP-1 RAs.

    Clinical Best Practices

    • Follow the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline as per trial protocol.
    • Ensure informed consent from all participants as per trial protocol.
    • Conduct safety assessments including vital signs and laboratory parameters as per trial protocol.

    Related Resources & Content

    Original Source(s)

    HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial

    • by Lixin Guo, Zilin Sun, Lihui Zhang, Guijun Qin, Yulan Li, Xiaopan Chen, Na Xu, Xiuhai Su, Li Mao, Jiao Sun, Zhifeng Cheng, Xiaoguang Shi, Fang Wang, Qi Wang, Ruirong Pan, Shan Ding, Zi Ye, Yimei Xu, Pan Liu

    • June 3, 2026

    Related Content

    Diabetic Retinal Disease Rates Narrow by Diabetes Type

    US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

    AACE 2026: Will AI replace endocrinologists?

    The same technology drawing patients away from clinic may also improve the patient-physician relationship.

    Comparative study of the therapeutic effects of different medications on DM-associated dry eye syndrome after vitrectomy